The Anti-ADAM9 Antibody (MGA021), also known as IMGC-936 antibody, is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the ADAM9 enzyme, a member of the disintegrin and metalloproteinase domain-containing protein family, which plays a crucial role in cellular signaling, adhesion, and migration. The Anti-ADAM9 Antibody (MGA021) is composed of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, and has a predicted molecular weight of 147.62 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended as a suitable isotype control for this antibody. This product is essential for researchers focusing on cancer biology, tissue remodeling, and inflammatory processes where ADAM9 is implicated.
The Anti-ADAM9 Antibody (MGA021), also known as IMGC-936 antibody, is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the ADAM9 enzyme, a member of the disintegrin and metalloproteinase domain-containing protein family, which plays a crucial role in cellular signaling, adhesion, and migration. The Anti-ADAM9 Antibody (MGA021) is composed of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, and has a predicted molecular weight of 147.62 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended as a suitable isotype control for this antibody. This product is essential for researchers focusing on cancer biology, tissue remodeling, and inflammatory processes where ADAM9 is implicated.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
